AM1428

AM1428 is a clinical-stage drug candidate developed by AMW GmbH, utilizing a proprietary biodegradable implant technology for the treatment of central nervous system (CNS) disorders. The asset is designed to provide sustained release of its active pharmaceutical ingredient, which may be a small molecule or peptide, aiming to improve treatment efficacy and patient adherence in chronic CNS conditions. The implant is formulated to degrade naturally in the body after the drug payload has been delivered. While the specific therapeutic indication and biological target remain confidential, the program is currently in the clinical phase of development.